Molecular Imaging of Mesenchymal Stem Cell: Mechanistic Insight Into Cardiac Repair After Experimental Myocardial Infarction

Background— Mesenchymal stem cells (MSCs) can differentiate into endothelial cells in vivo. However, it is unknown if the differentiated MSCs persist in vivo and if this potential persistence contributes to functional improvement after experimental myocardial infarction. Methods and Results— We generated a lentivector encoding 2 distinct reporter genes, one driven by a constitutive murine stem cell virus promoter and the other driven by an endothelial-specific Tie-2 promoter. The endothelial specificity of the lentivector was validated by its expression in endothelial cells but not in human MSCs (hMSCs). The lentivirus-transduced hMSCs were injected into peri-infarct areas of the hearts of severe combined immune-deficient mice. Persistence of injected cells was tracked by bioluminescence imaging (BLI) and verified by immunohistochemical staining. The BLI signal from the endothelial-specific reporter revealed that hMSCs differentiated into endothelial cells 48 hours after injection. However, both the constitutive and endothelial-specific BLI signals disappeared by day 50. Nonetheless, the improvement in left ventricle ejection fraction with hMSC therapy persisted for up to 6 months. Immunohistochemical staining showed that hMSC-derived endothelial cells integrated into endogenous CD31+ vessels. Furthermore, hMSC-transplanted hearts had more CD31+ vessels and a lesser degree of cardiac fibrosis compared with the controls at 6 months. Conclusions— hMSCs differentiated into endothelial cells and integrated into blood vessels after experimental myocardial infarction. The differentiated hMSCs only lasted for up to 50 days in vivo, but improvement in cardiac function persisted for up to 6 months. Increased angiogenesis and decreased fibrosis were associated with cardiac functional improvement after hMSC transplantation.

[1]  Phillip C. Yang,et al.  Mesenchymal Stem Cell Therapy for Cardiac Repair , 2014, Current Treatment Options in Cardiovascular Medicine.

[2]  Richard T. Lee,et al.  Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. , 2011, Cell stem cell.

[3]  Jakub Tolar,et al.  Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells , 2010, Stem cells.

[4]  L. Bidaut,et al.  Human CD34+ Cells in Experimental Myocardial Infarction: Long-Term Survival, Sustained Functional Improvement, and Mechanism of Action , 2010, Circulation research.

[5]  Stefanie Dimmeler,et al.  Mechanism of Improved Cardiac Function After Bone Marrow Mononuclear Cell Therapy: Role of Cardiovascular Lineage Commitment , 2010, Circulation.

[6]  Jianyi(Jay) Zhang,et al.  Long-term functional improvement and gene expression changes after bone marrow-derived multipotent progenitor cell transplantation in myocardial infarction. , 2010, American journal of physiology. Heart and circulatory physiology.

[7]  H. Drexler,et al.  Cell therapy for the treatment of coronary heart disease: a critical appraisal , 2010, Nature Reviews Cardiology.

[8]  G. Belcaro,et al.  Kidney function in metabolic syndrome may be improved with Pycnogenol®. , 2010, Panminerva medica.

[9]  G. I. Gallicano,et al.  Mesenchymal stem cell therapy for treatment of cardiovascular disease: helping people sooner or later. , 2010, Stem cells and development.

[10]  S. Janssens.  Stem cells in the treatment of heart disease. , 2010, Annual review of medicine.

[11]  C. Thiemermann,et al.  Mesenchymal Stromal Cells: Current Understanding and Clinical Status , 2009, Stem cells.

[12]  M. Andreeff,et al.  Direct Evidence of Mesenchymal Stem Cell Tropism for Tumor and Wounding Microenvironments Using In Vivo Bioluminescent Imaging , 2009, Stem cells.

[13]  N. Maulik,et al.  Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration. , 2009, Antioxidants & redox signaling.

[14]  Timothy O'Brien,et al.  Bone marrow-derived mesenchymal stem cells promote angiogenic processes in a time- and dose-dependent manner in vitro. , 2009, Tissue engineering. Part A.

[15]  B. Dawn,et al.  Bone marrow-derived mesenchymal stems cells and cardiac repair. , 2009, Minerva cardioangiologica.

[16]  V. Nurcombe,et al.  Wnt signaling controls the fate of mesenchymal stem cells. , 2009, Gene.

[17]  Ahmad Y. Sheikh,et al.  Comparison of Transplantation of Adipose Tissue- and Bone Marrow-Derived Mesenchymal Stem Cells in the Infarcted Heart , 2009, Transplantation.

[18]  Meijing Wang,et al.  VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. , 2008, American journal of physiology. Heart and circulatory physiology.

[19]  M. Gnecchi,et al.  Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy , 2008, Circulation research.

[20]  M. Eijken,et al.  Donor‐Derived Mesenchymal Stem Cells Remain Present and Functional in the Transplanted Human Heart , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  P. Hwu,et al.  Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer , 2008, Proceedings of the National Academy of Sciences.

[22]  S. Gronthos,et al.  Concise Review: Mesenchymal Stromal Cells: Potential for Cardiovascular Repair , 2008, Stem cells.

[23]  H. Northoff,et al.  Cardioprotection and cardiac regeneration by mesenchymal stem cells. , 2008, Panminerva medica.

[24]  Ralph Weissleder,et al.  A secreted luciferase for ex vivo monitoring of in vivo processes , 2008, Nature Methods.

[25]  Robert Passier,et al.  Monitoring of cell therapy and assessment of cardiac function using magnetic resonance imaging in a mouse model of myocardial infarction , 2007, Nature Protocols.

[26]  S. Kitamura,et al.  Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions , 2007, FEBS letters.

[27]  Xueli Yuan,et al.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis , 2007, Nature Medicine.

[28]  Timothy J Gardner,et al.  Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. , 2007, American journal of physiology. Heart and circulatory physiology.

[29]  R. Schwinger,et al.  Mesenchymal stem cells induce endothelial activation via paracine mechanisms. , 2007, Endothelium : journal of endothelial cell research.

[30]  Joshua M Hare,et al.  Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. , 2006, Journal of the American College of Cardiology.

[31]  J. Ingwall,et al.  Evidence supporting paracrine hypothesis for Akt‐modified mesenchymal stem cell‐mediated cardiac protection and functional improvement , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  Hidezo Mori,et al.  Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction , 2006, Nature Medicine.

[33]  R. Hurren,et al.  NKG2D splice variants: a reexamination of adaptor molecule associations , 2006, Immunogenetics.

[34]  R. Kloner,et al.  Allogeneic Mesenchymal Stem Cell Transplantation in Postinfarcted Rat Myocardium: Short- and Long-Term Effects , 2005, Circulation.

[35]  M. Gnecchi,et al.  Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. , 2005, Hypertension.

[36]  W. Vaughn,et al.  Mesenchymal Stem Cells Differentiate into an Endothelial Phenotype, Enhance Vascular Density, and Improve Heart Function in a Canine Chronic Ischemia Model , 2005, Circulation.

[37]  M. Burnett,et al.  Marrow-Derived Stromal Cells Express Genes Encoding a Broad Spectrum of Arteriogenic Cytokines and Promote In Vitro and In Vivo Arteriogenesis Through Paracrine Mechanisms , 2004, Circulation research.

[38]  James T. Willerson,et al.  Transdifferentiation of Human Peripheral Blood CD34+-Enriched Cell Population Into Cardiomyocytes, Endothelial Cells, and Smooth Muscle Cells In Vivo , 2003, Circulation.

[39]  J. Kantelip,et al.  Mesenchymal Progenitor Cells Differentiate into an Endothelial Phenotype, Enhance Vascular Density, and Improve Heart Function in a Rat Cellular Cardiomyoplasty Model , 2003, Circulation.

[40]  George E Taffet,et al.  Myocardial infarction and remodeling in mice: effect of reperfusion. , 1999, American journal of physiology. Heart and circulatory physiology.

[41]  Thomas N. Sato,et al.  Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  P. Doevendans,et al.  Mesenchymal stromal cells to treat cardiovascular disease: strategies to improve survival and therapeutic results. , 2010, Panminerva medica.

[43]  J. George.  Stem cell therapy in acute myocardial infarction: a review of clinical trials. , 2010, Translational research : the journal of laboratory and clinical medicine.

[44]  Paul D. Kessler,et al.  Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart , 2002, Circulation.